PTC Therapeutics (PTCT) Misses Q2 EPS by 11c

PTC Therapeutics (NASDAQ: PTCT) reported Q2 EPS of ($0.86), $0.11 worse than the analyst estimate of ($0.75). Revenue for the quarter came in at $1.7 million versus the consensus estimate of $1.71 million.

For earnings history and earnings-related data on PTC Therapeutics (PTCT) click here.

You May Also Be Interested In

• Nvidia pitches Vera CPU to Chinese clients with August delivery target
• Sharon AI secures six-year compute deal with NVIDIA for Australia deployment
• Carvana (CVNA) PT Lowered to $85 at RBC Capital